Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies

Rhea-AI Summary

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) has been ranked 4th on Forbes' list of America's Most Successful Small-Cap Companies for 2024. The ranking is based on positive sales growth over the last twelve months and includes criteria such as earnings growth, sales growth, return on equity, and total stock return. Catalyst's Chairman and CEO, Patrick J. McEnany, expressed gratitude for the recognition and attributed the company's success to the dedication of its employees and commitment to rare disease patient communities.

Catalyst Ranked #4 on the List

CORAL GABLES, Fla., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most Successful Small-Cap Companies for the year 2024. Catalyst has ranked an impressive 4th out of 100 companies on this prestigious list, which recognizes small-cap companies that have demonstrated positive sales growth over the last twelve months.

"We are very honored to be recognized among the top companies in the Forbes 2024 Most Successful Small-Cap Companies. It is gratifying to receive this prestigious recognition for the substantial growth we achieved, which is a testament to our exceptional capabilities,” stated Patrick J. McEnany, Chairman and CEO of Catalyst. “Our many accomplishments over the past year reflect the unwavering dedication of all our employees and our steadfast commitment to the rare disease patient communities we proudly serve. As we forge ahead, we are resolute in harnessing our strengths for sustained growth and driving value for our stakeholders.”

For the ranking, Forbes assessed over 1,000 small-cap companies and narrowed it down to 389 companies that demonstrated positive sales growth over the past twelve months and maintained a minimum share price of $5. These stocks were subsequently ranked based on criteria such as earnings growth, sales growth, return on equity, and total stock return for the most recent 12-month period and the preceding five years. Forbes used data from FactSet to compile its annual list of America’s Most Successful Small-Cap Companies; all data was as of November 3, 2023.

About Catalyst Pharmaceuticals

With exceptional patient focus, Catalyst is committed to developing and commercializing innovative first-in-class medicines that address rare neurological and epileptic diseases. Catalyst's flagship U.S. commercial product is FIRDAPSE^® (amifampridine) Tablets 10 mg, approved for the treatment of Lambert Eaton myasthenic syndrome ("LEMS") for adults and for children ages six to seventeen. In January 2023, Catalyst acquired the U.S. commercial rights to FYCOMPA^® (perampanel) CIII, a prescription medicine approved in people with epilepsy aged four and older alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures and with other medicines to treat primary generalized tonic-clonic seizures for people with epilepsy aged 12 and older. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS. Finally, on July 18, 2023, Catalyst acquired an exclusive license for North America for AGAMREE^® (vamorolone) oral suspension 40 mg/mL, a novel corticosteroid treatment for Duchenne Muscular Dystrophy.  AGAMREE previously received FDA Orphan Drug and Fast Track designations and was approved by the FDA for commercialization in the U.S. on October 26, 2023.

For more information about  Catalyst Pharmaceuticals, Inc., visit the Company's website at www.catalystpharma.com. For Full Prescribing and Safety Information for FIRDAPSE^®, visit www.firdapse.com. For Full Prescribing Information, including Boxed WARNING for FYCOMPA^®, please visit www.fycompa.com. For Full Prescribing Information for AGAMREE^®, please visit https://www.agamree.com/.

Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2022 and its other filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Source: Catalyst Pharmaceuticals, Inc.

FAQ

What is Catalyst Pharmaceuticals, Inc.'s ranking on Forbes' list of America's Most Successful Small-Cap Companies for 2024?

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) has been ranked 4th on Forbes' list of America's Most Successful Small-Cap Companies for 2024.

What criteria were used for the ranking on Forbes' list of America's Most Successful Small-Cap Companies for 2024?

The ranking is based on positive sales growth over the last twelve months and includes criteria such as earnings growth, sales growth, return on equity, and total stock return.

Who is the Chairman and CEO of Catalyst Pharmaceuticals, Inc.?

Patrick J. McEnany is the Chairman and CEO of Catalyst Pharmaceuticals, Inc.

What attributed to Catalyst Pharmaceuticals, Inc.'s success according to the PR?

Patrick J. McEnany attributed the company's success to the dedication of its employees and commitment to rare disease patient communities.